Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma

Clinical trials in oncology often allow patients randomized to placebo to cross over to the active treatment arm after disease progression, leading to underestimation of the treatment effect on overall survival as per the intention-to-treat analysis. We illustrate the statistical aspects and practical use of the rank-preserving structural failure time (RPSFT) model with the Fleming–Harrington family of tests to estimate the crossover-corrected treatment effect, and to assess its sensitivity to various weighting schemes in the RECORD-1 trial. The results suggest that the benefit demonstrated in progression-free survival is likely to translate into a robust overall survival benefit.

[1]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[2]  Stephen R Cole,et al.  Inverse probability‐of‐censoring weights for the correction of time‐varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death , 2009, Statistics in medicine.

[3]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[4]  Patrick Schöffski,et al.  Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure , 2008 .

[5]  R. Amato,et al.  A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Robins.  Structural Nested Failure Time Models , 2005 .

[7]  J. Robins,et al.  Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pds.1064 , 2022 .

[8]  S. Cole,et al.  Effect of acyclovir on herpetic ocular recurrence using a structural nested model. , 2005, Contemporary clinical trials.

[9]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[11]  N M Laird,et al.  Correcting for non-compliance in randomized trials: an application to the ATBC Study. , 1999, Statistics in medicine.

[12]  Ian R. White,et al.  Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. , 1999, Statistics in medicine.

[13]  P. Holland.  Statistics and Causal Inference , 1985 .

[14]  Michael Rosenblum,et al.  Marginal Structural Models , 2011 .

[15]  J. Thigpen.  Issues in Using Progression-Free Survival When Evaluating Oncology Products , 2010 .

[16]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) DRAFT GUIDELINE ON THE EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN , 2005 .

[17]  James M. Robins,et al.  Marginal Structural Models versus Structural nested Models as Tools for Causal inference , 2000 .

[18]  J. Robins,et al.  Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .

[19]  David P. Harrington,et al.  A class of hypothesis tests for one and two sample censored survival data , 1981 .

[20]  Donald B. Rubin,et al.  Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .